our Premium Content: News alerts, weekly reports and conference planners

DRUG:

quemliclustat (AB680)

News alerts, weekly reports and conference planners

Company:

Arcus Biosciences, Gilead, Otsuka

Drug class:

CD73 inhibitor

In a phase 1b trial (ARC-8), we evaluated safety and efficacy of quemliclustat combined with gemcitabine/nab-paclitaxel (G/nP) with or without zimberelimab (anti-programmed cell death protein 1 (PD-1)) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC)...High tumor NR4A expression was associated with improved overall survival (OS) in ARC-8 but not in two external cohorts from the PRINCE (G/nP + nivolumab (nivo)) or Morpheus-PDAC (G/nP) trials...In paired pretreatment/posttreatment biopsies, maximal downregulation of NR4A expression was associated with T cell activation and improved OS, pointing to a biological link between tumor adenosine and clinical benefit. ClinicalTrials.gov identifier: NCT04104672 .

7 days ago

P1 data • Journal • PD(L)-1 Biomarker • IO biomarker

CD73 (5'-Nucleotidase Ecto) • NR4A1 (Nuclear Receptor Subfamily 4 Group A Member 1)

Opdivo (nivolumab) • gemcitabine • albumin-bound paclitaxel • Yutuo (zimberelimab) • quemliclustat (AB680)

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) (clinicaltrials.gov)

P1, N=8, Active, not recruiting, Arcus Biosciences, Inc. | Recruiting --> Active, not recruiting

1 month ago

Enrollment closed

quemliclustat (AB680)

2ms

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) (clinicaltrials.gov)

P1, N=8, Recruiting, Arcus Biosciences, Inc. | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

quemliclustat (AB680)

2ms

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) (clinicaltrials.gov)

P1, N=8, Not yet recruiting, Arcus Biosciences, Inc.

2 months ago

New P1 trial

quemliclustat (AB680)

3ms

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov)

P1/2, N=56, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

3 months ago

Trial completion date • Trial primary completion date

oxaliplatin • irinotecan • Yutuo (zimberelimab) • leucovorin calcium • fluorouracil topical • quemliclustat (AB680)

3ms

Potent Competitive Inhibitors of Ecto-5'-nucleotidase (CD73) based on 6‑(Het)aryl-7-deazapurine Ribonucleoside 5'‑O‑Bisphosphonates. (PubMed, ACS Pharmacol Transl Sci)

They effectively suppressed adenosine formation in MDA-MB-231 cells, rescued CD8+ T cell activation, and were nontoxic to human fibroblasts. Overall, their profile compares favorably with AB680, a CD73 inhibitor currently in phase I/II clinical trials.

3 months ago

Journal

CD8 (cluster of differentiation 8) • CD73 (5'-Nucleotidase Ecto) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)

quemliclustat (AB680)

6ms

ARC-9: An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. (clinicaltrials.gov)

P1/2, N=227, Completed, Arcus Biosciences, Inc. | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Sep 2025

6 months ago

Trial completion • Trial completion date

Avastin (bevacizumab) • 5-fluorouracil • Stivarga (regorafenib) • Yutuo (zimberelimab) • leucovorin calcium • etrumadenant (AB928) • quemliclustat (AB680)

6ms

EDGE-Lung: Study With Various Immunotherapy Treatments in Participants With Lung Cancer (clinicaltrials.gov)

P2, N=400, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting

6 months ago

Enrollment closed

docetaxel • Yutuo (zimberelimab) • domvanalimab (AB154) • quemliclustat (AB680)

6ms

PRISM-1: Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)

P3, N=610, Active, not recruiting, Arcus Biosciences, Inc. | Recruiting --> Active, not recruiting

6 months ago

Enrollment closed

gemcitabine • albumin-bound paclitaxel • quemliclustat (AB680)

8ms

ARC-9: An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. (clinicaltrials.gov)

P1/2, N=227, Active, not recruiting, Arcus Biosciences, Inc. | Trial completion date: Aug 2025 --> Mar 2026 | Trial primary completion date: Jul 2025 --> Oct 2025

8 months ago

Trial completion date • Trial primary completion date

Avastin (bevacizumab) • 5-fluorouracil • Stivarga (regorafenib) • Yutuo (zimberelimab) • leucovorin calcium • etrumadenant (AB928) • quemliclustat (AB680)

10ms

CD73 inhibitor AB680 suppresses glioblastoma in mice by inhibiting purine metabolism and promoting P2RY12+ microglia transformation. (PubMed, Acta Pharmacol Sin)

Overall, this study demonstrates that targeting CD73 with AB680 alters purine metabolism in the GBM microenvironment, promotes the transformation of P2RY12+ microglia, and triggers robust anti-tumor immune responses. These results support the rationale for AB680-based therapeutic clinical trials for GBM.

10 months ago

Preclinical • Journal

CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)

quemliclustat (AB680)

10ms

EDGE-Gastric: A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (clinicaltrials.gov)

P2, N=332, Active, not recruiting, Arcus Biosciences, Inc. | Trial primary completion date: Sep 2026 --> Jan 2027

10 months ago

Trial primary completion date • IO biomarker

PD-L1 (Programmed death ligand 1)

5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154) • quemliclustat (AB680)